What stage does Novalis Biotech invest at?

Novalis Biotech invests at the Pre-Seed, Seed, Series A stages.

Where is Novalis Biotech located?

Novalis Biotech is headquartered in Ghent, BE.

Novalis Biotech

Venture capital

Ghent · Pre-Seed–Series A · 9 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Novalis Biotech invests early in life sciences companies building enabling technologies. It favors capital-light platform technologies and close, early engagement with customers. Priority focus areas include innovative research and manufacturing tools, bioinformatics, genomics, diagnostics, and digital health. The firm targets pre-seed through Series A startups, often coming in at the point of incorporation, and supports their growth by providing funding, sharing professional and academic connections, and helping shape business strategy to create value for all stakeholders.

Invests inAI & Machine Learning Biotech Digital Health FoodTech Healthtech Medical DevicesBelgiumEuropeFranceGermanyNetherlandsPortugalSwitzerlandUnited States

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Series A

Ghent, BE

Instruments

Equity

Founded

2018

Tracked investments

Team · 9 people

from the firm's website & public directories

Jan Van den Berghe· Founder· Cranbrook, England, United Kingdomin

Jan Van den Berghe co-founded Novalis Biotech Incubation with Wim. An entrepreneur in the food and biotech sectors, he trained as a bio-engineer and previously worked as a senior consultant at the Boston Consulting Group and as an independent strategy consultant. He co-founded and served as director of Genohm, which Agilent Technologies acquired in 2018, and holds an MBA from INSEAD and a Master in General Management from Vlerick Management School.

j•••@noval.isreveal

Wim Van Criekinge· Founder, Novalis Biotech Incubation· Ghent, Belgiumin

Wim Van Criekinge holds a PhD and is a tenured professor of computational genomics and bioinformatics at Ghent University, where he founded and leads the BIOBIX lab and the NXTGNT core sequencing facility. Together with Jan, he co-founded Novalis Biotech Incubation, and he has co-founded biotech startups including Devgen and Genohm. He currently serves as CSO of MDxHealth, a public biotech company focused on uro-oncology, and holds several biotech startup board seats. He earned a Master's in Chemical Engineering and a PhD in Molecular Biology (1998) from the University of Ghent.

w•••@noval.isreveal

Kjell Mortier· Fund Manager· Ghent Metropolitan Areain

Kjell Mortier (Pharm., PhD) is a Fund Manager at Novalis. He has around 20 years of experience in the biotech industry across scientific roles in large pharma and CDMO companies, including work on bioanalytical and immunogenicity aspects of (pre-)clinical programs at Ablynx (now part of Sanofi) and CMC-analytical support and technology evaluation at the CRO Eurofins. He also holds a certification in financial analysis from EHSAL Management School.

k•••@noval.isreveal

Jaroslav Belotserkovsky· Investment Manager· Leuven, Flemish Region, Belgiumin

Jaroslav Belotserkovsky holds a master's in molecular genetics from the University of Witwatersrand in South Africa and a PhD from Stockholm University in Sweden. His background spans life sciences, health technology, entrepreneurship, and management, including prior roles as an Innovation Manager at KU Leuven, a part-time position in the Department of Oncology, and work on an independent health-tech startup project.

j•••@noval.isreveal

Bart Rossel· Scientific Advisor and Advisory Board Member, Novalis Biotech Incubation Fund; Supervisory Board Member of Novalis

Bart Rossel is a bio-engineer by training who has worked in the agro and life science sectors and held several management roles. In 2002, he and his team acquired the pharmaceutical company Oystershell Laboratories, which they sold to Gilde Buy Out Partners in 2017. He holds several patents and authored a book about insects.

Cedric Bogaert· Entrepreneur in Residencein

Cedric Bogaert is an Entrepreneur in Residence at Novalis Biotech, currently managing myNEO. His background includes epigenomic research at UGent and immunovaccine development research at VUB. He previously worked as a pricing architectural lead at Accenture.

Kathleen Van den Berghe· Member of the Supervisory Boardin

Kathleen Van den Berghe serves on the Supervisory Board of Novalis. She has over 20 years of professional experience as a consultant, entrepreneur, employee, and employer across a wide range of industries, with international work on multiple continents. Her stated areas of expertise include strategy and analysis, construction and industry, and wine and tourism.

Liesbeth Ceelen· CEO of BioLizardin

Liesbeth Ceelen holds a PhD in veterinary sciences and began her career at J&J before moving into biotech and healthcare start-ups and scale-ups, where she worked across operations, quality, project management, scientific leadership, sales, and business development. She is currently CEO of BioLizard, a data analytics and data engineering company. She is involved with the Healthcare Businesswomen's Association and the TOPX Network for Women in Life Sciences, and received the Inspiring 50 STEM award in 2022.

Michael Hengartner· Scientific Advisor and Advisory Board Member, Novalis Biotech Incubation Fund· Zurich, Switzerland

Michael Hengartner serves as a Scientific Advisor and Advisory Board Member for the Novalis Biotech Incubation Fund. He is president of the board of ETH in Zurich, Switzerland, and previously served as rector of the University of Zurich from 2014 to 2019. He earned his PhD in 1994 at the Massachusetts Institute of Technology under Nobel Laureate H. Robert Horvitz, led a research group at Cold Spring Harbor Laboratory until 2001, and became a professor of molecular biology at the University of Zurich, where he also served as dean of the Faculty of Science from 2009 to 2014.

What they invest in

from 15 of 20 portfolio companies

Biotech ×8Healthtech ×8Medical Devices ×8AI & Machine Learning ×6Deep Tech ×5Digital Health ×5Hardware ×2Advanced Manufacturing ×1

HQs:Belgium×2United States×2Germany×1France×1

Investments · 20 tracked

founders shown can be your intro path

Trincetrincebio.comin✓ verified

Trince is a Ghent University spin-off developing photoporation technology for physical transfection of cells as an alternative to viral vectors and electroporation.

BiotechDeep TechMedical DevicesGent, BE

PhilipKevin

Alithea Genomicsalitheagenomics.com

Altavoaltavo.eu

Altavo develops non-invasive silent speech technology using RF sensing and artificial intelligence to help patients who have lost their voice regain natural-sounding speech.

AI & Machine LearningDeep TechMedical DevicesDresden, DE

RudolfTimoLydiaStephanieDominikChristoph

C-mo Medical Solutionsc-mo.solutionsin

C-mo develops an automated wearable device that records and analyzes cough patterns in real-time for continuous patient monitoring.

Digital HealthHealthtechMedical Devices

Carroucellcarroucell.comin

Carroucell develops microcarrier technology for cell and gene therapy applications, enabling cost-effective bioproduction and cell amplification.

BiotechDeep TechMedical DevicesGrenoble, FR

Tarek Fathallah

Cergentiscergentis.comin

Cergentis provides genetic characterization and quality control services built on its Targeted Locus Amplification (TLA) technology platform, supporting the development of advanced therapies for pharma and biotech clients.

BiotechDeep TechHealthtech

Clouds of Care NVcloudsofcare.comin

Clouds of Care develops EEG and electrophysiology-based digital health technology and software (including FDA-cleared/CE-marked SaMD) to provide meaningful endpoints for clinical development in CNS disorders such as epilepsy and sleep disorders.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Docdoc.ai

HealthtechBoise, US

Hassinger David(Executive Officer)

Enzyreenzyre.com

Enzyre develops the ENZYSYSTEM, a near-patient blood coagulation testing platform consisting of a blood sampling device, a single-use microfluidic cartridge with reagents, and a reusable processor that measures enzymatic activity in the coagulation cascade and transfers results to the cloud via a mobile app.

BiotechDigital HealthMedical Devices

Fertigafertiga.com

Fertiga is a biotech spin-off from UZ Brussel and Vrije Universiteit Brussel that develops the Aurora niPCT, a non-invasive diagnostic test analysing the cumulus cells surrounding oocytes to rank egg quality and identify the embryo with the highest chance of a live birth.

BiotechDigital HealthFemTech

Graphealgrapheal.com

Grapheal develops graphene-based biosensors, including PFAST, a field-deployable device for fast, real-time detection of ultra-trace PFAS ("forever chemicals") in water.

CleantechDeep TechHardware

H42 Inc

US company developing an epigenetic clock and diagnostics, providing multiple biological readouts from a single assay, with applications in rheumatoid arthritis, colorectal cancer screening, and skin-age.

Lizardlizard.bioin

BioLizard provides data analytics and AI solutions that turn biomedical and scientific data into insights for pharma and biotech organizations.

AI & Machine LearningBiotechHealthtech

Modalitymodality.ai

Modality.AI develops an AI-based multimodal assessment platform that uses app-collected data to help diagnose and monitor neurodegenerative diseases such as ALS.

AI & Machine LearningDigital HealthHealthtechMedical Devices

David Suendermann-Oeft(Co-founder & CEO)David Pautler(Co-founder & CTO)

myNEO Therapeuticsmyneotx.comin

myNEO develops the ImmunoEngine platform, a modular suite of AI-driven technologies for immune target discovery, prioritization, and optimization, covering personalized neoantigen discovery, codon optimization, construct design, ADA risk prediction, and epitope screening.

AI & Machine LearningBiotechHealthtech

Ohmx in

Evanston, US

SCOTT HALL(Director)BRIAN DYSON(Director)KIM ARVANITES(Director)BARBARA BEUG DYSON(Director)STUART CORNEW(Director)THOMAS MEADE(Director)

pEGGy BV

Belgian food technology company developing novel solutions for the egg hatching sector; Novalis is a founding investor.

Rarity Bioscienceraritybioscience.com

RheaVitarheavita.comin

RheaVita develops the RheaLyo continuous, controlled GMP-ready freeze-drying (lyophilization) technology for high-value biologics such as drugs and vaccines.

Advanced ManufacturingBiotechHardware

RheumaFinderrheumafinder.aiin

RheumaFinder is an AI-powered application that analyzes CT images to detect structural bone lesions in the sacroiliac joints, intended to support radiologists in identifying patients with rheumatic disease.

AI & Machine LearningHealthtechMedical Devices

Frequently asked questions

What stage does Novalis Biotech invest at?: Novalis Biotech invests at the Pre-Seed, Seed, Series A stages.
What sectors does Novalis Biotech focus on?: Novalis Biotech focuses on AI & Machine Learning, Biotech, Digital Health, FoodTech, Healthtech, Medical Devices.
Where is Novalis Biotech located?: Novalis Biotech is headquartered in Ghent, BE.

Images

Similar investors

DCVC (Data Collective)

DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.

$5M – $25M

Snatched Ventures

Snatched Ventures is a venture capital firm that partners with entrepreneurs pursuing bold, transformative visions, offering strategic support to help scale breakthrough innovations.

Voima Ventures

Voima Ventures is a deep tech venture capital firm that backs founders building global solutions across people, planet, and industry, from technology spin-offs to scaling companies.

$216K – $3.2M

Rockies Venture Club

Rockies Venture Club is an angel investor network of 100+ active members focused on Seed to Series A opportunities, offering due diligence, syndication nationwide, and educational programming for investors and entrepreneurs.

$100K – $500K

VTC Ventures

VTC Ventures is an early-stage venture fund managed by Middleland Capital and backed by strategic LPs including Virginia Tech, the Fralin Biomedical Research Institute, and Carilion Clinic. It invests in healthcare, deep tech/defense/AI, and food & agriculture, offering founders access to clinical, research, and commercialization resources.

$100K – $5M